We are live on
!
Find out more
ITP
Iron Triangle Partners Portfolio holdings
AUM
$875M
1-Year Est. Return
49.85%
This Fund
S&P 500
This Quarter
Est. Return
+22.34%
1 Year Est. Return
+49.85%
3 Year Est. Return
+151.9%
5 Year Est. Return
+239.84%
10 Year Est. Return
–
AUM
$558M
AUM Growth
-$14.3M
(-2.5%)
Cap. Flow
-$80.4M
Cap. Flow
% of AUM
-14.41%
Top 10 Holdings %
Top 10 Hldgs %
63.48%
Holding
36
New
9
Increased
4
Reduced
13
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cooper Companies
COO
|
+$36.3M |
| 2 |
Universal Health Services
UHS
|
+$35.4M |
| 3 |
Gilead Sciences
GILD
|
+$29.6M |
| 4 |
Icon
ICLR
|
+$28M |
| 5 |
Surgery Partners
SGRY
|
+$19.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Neurocrine Biosciences
NBIX
|
+$29.9M |
| 2 |
HealthEquity
HQY
|
+$29.6M |
| 3 |
Cigna
CI
|
+$26.3M |
| 4 |
Guardant Health
GH
|
+$26.2M |
| 5 |
HCA Healthcare
HCA
|
+$25.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Stereotaxis
STXS
$130M
| $3.46M | 0.62% |
1,671,109
-25,490
| -2% | -$49.8K |
|
27
Alnylam Pharmaceuticals
ALNY
$37.2B
| – | – |
-80,000
| Closed | -$16M |
|
28
Bio-Rad Laboratories Class A
BIO
$8.47B
| – | – |
-50,000
| Closed | -$20.9M |
|
|
29
Guardant Health
GH
$19.3B
| – | – |
-487,193
| Closed | -$26.2M |
|
|
30
HCA Healthcare
HCA
$86.4B
| – | – |
-140,000
| Closed | -$25.7M |
|
|
31
HealthEquity
HQY
$8.28B
| – | – |
-440,000
| Closed | -$29.6M |
|
32
Humana
HUM
$45.8B
| – | – |
-35,000
| Closed | -$17M |
|
33
Insulet
PODD
$11.4B
| – | – |
-80,000
| Closed | -$18.4M |
|
|
CTLT
34
DELISTED
CATALENT, INC.
CTLT
| – | – |
-250,000
| Closed | -$18.1M |
|
|
OHPAU
35
DELISTED
Orion Acquisition Corp. Unit
OHPAU
| – | – |
-999,513
| Closed | -$9.87M |
|
|
HZNP
36
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| – | – |
-265,076
| Closed | -$16.4M |
|
Similar funds
8KM
MFG
NP
GGI
WFAL
OBWP
TWM
AGC
Iron Triangle Partners's Q4 2022 Portfolio in Review
As of Q4 2022, Iron Triangle Partners held 36 positions worth $558M, down 2.5% from $572M the previous quarter. Its ten largest holdings account for 63% of the portfolio.
Iron Triangle Partners withdrew a net $80.4M in Q4 2022, closing 10 positions and reducing 13 holdings. Its most notable exit was HealthEquity, an estimated $29.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier.
Against the trend, Iron Triangle Partners opened a new position in Cooper Companies worth $40.7M.
- Iron Triangle Partners's largest Q4 2022 buy was Cooper Companies: 492,000 shares worth $40.7M.
- Iron Triangle Partners added most to Icon in Q4 2022, an estimated $28M increase.
- Iron Triangle Partners's biggest Q4 2022 reduction was Neurocrine Biosciences, cutting an estimated $29.9M.
- Iron Triangle Partners fully exited HealthEquity in Q4 2022, selling an estimated $29.6M.
- Iron Triangle Partners's ten largest holdings make up 63% of its $558M portfolio in Q4 2022.
- Iron Triangle Partners opened 9 new positions and closed 10 in Q4 2022.
- Iron Triangle Partners's portfolio value fell 2.5% quarter-over-quarter to $558M.
Based on Iron Triangle Partners's 13F filing for Q4 2022, filed 14 Feb 2023.